ARK Genomic Revolution ETF vs YieldMax TSLA Option Income Strategy ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while YieldMax TSLA Option Income Strategy ETF trades at $21.64. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | TSLY | |
|---|---|---|
Sector | Sector/Thematic | Income / Options Overlay |
52-Week High | $44.55 | $48.25 |
52-Week Low | $24.02 | $20.49 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
TSLY trades at $21.57, down 0.74% today, with a bearish technical outlook indicated by moving averages and key indicators. The ETF generates substantial income through weekly distributions, with recent dividends ranging from $0.23 to $0.52 per share. However, the structure caps upside potential during Tesla rallies, as noted in recent analyst commentary.
While TSLY offers high yield potential through its option income strategy, investors face significant risks including capped upside capture, volatility exposure from Tesla's underlying performance, and potential return of capital distributions. The neutral sentiment from oscillators suggests limited near-term directional momentum.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →